

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
22 June 2006 (22.06.2006)

PCT

(10) International Publication Number
WO 2006/065215 A1

(51) International Patent Classification:

C07D 401/14 (2006.01) *A61P 19/02* (2006.01)
A61K 31/444 (2006.01) *A61P 35/00* (2006.01)
A61K 31/506 (2006.01) *A61P 9/10* (2006.01)
A61P 11/06 (2006.01) *C07D 471/04* (2006.01)

(74) Agent: ASTRAZENECA; Global Intellectual Property,
S-151 85 Södertälje (SE).

(21) International Application Number:

PCT/SE2005/001917

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date:

14 December 2005 (14.12.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0403085-4 17 December 2004 (17.12.2004) SE

(71) Applicant (for all designated States except US): ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GABOS, Balint** [SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE). **LUNDKVIST, Michael** [SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE). **MUNCK AF ROSEN-SCHÖLD, Magnus** [SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE). **SHAMOVSKY, Igor** [CA/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE). **ZLATOIDSKY, Pavol** [SK/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE).


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL COMPOUNDS



(57) Abstract: The invention provides compounds of formula (I): wherein R¹, R², A, A¹ and B are as defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy. The compounds are useful as MMP inhibitors.

NOVEL COMPOUNDS

The present invention relates to novel hydantoin derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

5

Metalloproteinases are a superfamily of proteinases (enzymes) whose numbers in recent years have increased dramatically. Based on structural and functional considerations these enzymes have been classified into families and subfamilies as described in N.M. Hooper (1994) FEBS Letters 354:1-6. Examples of metalloproteinases include the matrix metalloproteinases (MMPs) such as the collagenases (MMP1, MMP8, MMP13), the gelatinases (MMP2, MMP9), the stromelysins (MMP3, MMP10, MMP11), matrilysin (MMP7), metalloelastase (MMP12), enamelysin (MMP19), the MT-MMPs (MMP14, MMP15, MMP16, MMP17); the reprotoxin or adamalysin or MDC family which includes the secretases and sheddases such as TNF converting enzymes (ADAM10 and TACE); the astacin family which include enzymes such as procollagen processing proteinase (PCP); and other metalloproteinases such as aggrecanase, the endothelin converting enzyme family and the angiotensin converting enzyme family.

10

Metalloproteinases are believed to be important in a plethora of physiological disease processes that involve tissue remodelling such as embryonic development, bone formation and uterine remodelling during menstruation. This is based on the ability of the metalloproteinases to cleave a broad range of matrix substrates such as collagen, proteoglycan and fibronectin. Metalloproteinases are also believed to be important in the processing, or secretion, of biological important cell mediators, such as tumour necrosis factor (TNF); and the post translational proteolysis processing, or shedding, of biologically important membrane proteins, such as the low affinity IgE receptor CD23 (for a more complete list see N. M. Hooper *et al.*, (1997) Biochem. J. 321:265-279).

15

Metalloproteinases have been associated with many diseases or conditions. Inhibition of the activity of one or more metalloproteinases may well be of benefit in these diseases or conditions, for example: various inflammatory and allergic diseases such as, inflammation of the joint (especially rheumatoid arthritis, osteoarthritis and gout), inflammation of the

20

gastro-intestinal tract (especially inflammatory bowel disease, ulcerative colitis and gastritis), inflammation of the skin (especially psoriasis, eczema, dermatitis); in tumour metastasis or invasion; in disease associated with uncontrolled degradation of the extracellular matrix such as osteoarthritis; in bone resorptive disease (such as osteoporosis and Paget's disease); in diseases associated with aberrant angiogenesis; the enhanced collagen remodelling associated with diabetes, periodontal disease (such as gingivitis), corneal ulceration, ulceration of the skin, post-operative conditions (such as colonic anastomosis) and dermal wound healing; demyelinating diseases of the central and peripheral nervous systems (such as multiple sclerosis); Alzheimer's disease; extracellular matrix remodelling observed in cardiovascular diseases such as restenosis and atherosclerosis; asthma; rhinitis; and chronic obstructive pulmonary diseases (COPD).

MMP12, also known as macrophage elastase or metalloelastase, was initially cloned in the mouse by Shapiro *et al* [1992, *Journal of Biological Chemistry* 267: 4664] and in man by the same group in 1995. MMP12 is preferentially expressed in activated macrophages, and has been shown to be secreted from alveolar macrophages from smokers [Shapiro *et al*, 1993, *Journal of Biological Chemistry*, 268: 23824] as well as in foam cells in atherosclerotic lesions [Matsumoto *et al*, 1998, *Am. J. Pathol.* 153: 109]. A mouse model of COPD is based on challenge of mice with cigarette smoke for six months, two cigarettes a day six days a week. Wild-type mice developed pulmonary emphysema after this treatment. When MMP12 knock-out mice were tested in this model they developed no significant emphysema, strongly indicating that MMP12 is a key enzyme in the COPD pathogenesis. The role of MMPs such as MMP12 in COPD (emphysema and bronchitis) is discussed in Anderson and Shinagawa, 1999, *Current Opinion in Anti-inflammatory and Immunomodulatory Investigational Drugs* 1(1): 29-38. It was recently discovered that smoking increases macrophage infiltration and macrophage-derived MMP-12 expression in human carotid artery plaques Kangavari [Matetzky S, Fishbein MC *et al*., *Circulation* 102:(18), 36-39 Suppl. S, Oct 31, 2000].

MMP9 (Gelatinase B; 92kDa TypeIV Collagenase; 92kDa Gelatinase) is a secreted protein which was first purified, then cloned and sequenced, in 1989 [S.M. Wilhelm *et al* (1989) *J. Biol. Chem.* 264 (29): 17213-17221; published erratum in *J. Biol. Chem.* (1990) 265

(36): 22570]. A recent review of MMP9 provides an excellent source for detailed information and references on this protease: T.H. Vu & Z. Werb (1998) (In : Matrix Metalloproteinases, 1998, edited by W.C. Parks & R.P. Mecham, pp. 115 – 148, Academic Press. ISBN 0-12-545090-7). The following points are drawn from that review by T.H. Vu & Z. Werb (1998).

The expression of MMP9 is restricted normally to a few cell types, including trophoblasts, osteoclasts, neutrophils and macrophages. However, the expression can be induced in these same cells and in other cell types by several mediators, including exposure of the 10 cells to growth factors or cytokines. These are the same mediators often implicated in initiating an inflammatory response. As with other secreted MMPs, MMP9 is released as an inactive Pro-enzyme which is subsequently cleaved to form the enzymatically active enzyme. The proteases required for this activation *in vivo* are not known. The balance of active MMP9 versus inactive enzyme is further regulated *in vivo* by interaction with 15 TIMP-1 (Tissue Inhibitor of Metalloproteinases -1), a naturally-occurring protein. TIMP-1 binds to the C-terminal region of MMP9, leading to inhibition of the catalytic domain of MMP9. The balance of induced expression of ProMMP9, cleavage of Pro- to active MMP9 and the presence of TIMP-1 combine to determine the amount of catalytically active 20 MMP9 which is present at a local site. Proteolytically active MMP9 attacks substrates which include gelatin, elastin, and native Type IV and Type V collagens; it has no activity against native Type I collagen, proteoglycans or laminins.

There has been a growing body of data implicating roles for MMP9 in various 25 physiological and pathological processes. Physiological roles include the invasion of embryonic trophoblasts through the uterine epithelium in the early stages of embryonic implantation; some role in the growth and development of bones; and migration of inflammatory cells from the vasculature into tissues.


MMP9 release, measured using enzyme immunoassay, was significantly enhanced in fluids 30 and in AM supernatants from untreated asthmatics compared with those from other populations [Am. J. Resp. Cell & Mol. Biol., Nov 1997, 17 (5):583-591]. Also, increased MMP9 expression has been observed in certain other pathological conditions, thereby

implicating MMP9 in disease processes such as COPD, arthritis, tumour metastasis, Alzheimer's disease, multiple sclerosis, and plaque rupture in atherosclerosis leading to acute coronary conditions such as myocardial infarction.

5 A number of metalloproteinase inhibitors are known (see, for example, the reviews of MMP inhibitors by Beckett R.P. and Whittaker M., 1998, *Exp. Opin. Ther. Patents*, 8(3):259-282; and by Whittaker M. *et al*, 1999, *Chemical Reviews* 99(9):2735-2776).

WO 02/074767 discloses hydantoin derivatives of formula

10




that are useful as MMP inhibitors, particularly as potent MMP12 inhibitors.

15 We now disclose a further group of hydantoin derivatives that are inhibitors of metalloproteinases and are of particular interest in inhibiting MMPs such as MMP12 and MMP9. The compounds of the present invention have beneficial potency, selectivity and/or pharmacokinetic properties.

In accordance with the present invention, there are provided compounds of formula (I)

20



wherein

R^1 represents cyclobutyl or cyclopropyl; said cyclopropyl group being optionally further substituted by CH_3 , CN or one or two fluoro atoms;

5 R^2 represents C1 to 3 alkyl or cyclopropyl; and

A , A^1 and B independently represent CH or N;

and pharmaceutically acceptable salts thereof.

10

The compounds of formula (I) may exist in enantiomeric forms. It is to be understood that all enantiomers, diastereomers, racemates and mixtures thereof are included within the scope of the invention.

15

Compounds of formula (I) may also exist in various tautomeric forms. All possible tautomeric forms and mixtures thereof are included within the scope of the invention.

In one embodiment, R^1 represents cyclopropyl; said cyclopropyl group being optionally further substituted by one or two fluoro atoms.

20

In one embodiment, R^1 represents cyclopropyl.

In one embodiment, R^2 represents methyl or ethyl. In one embodiment, R^2 represents methyl.

25

In one embodiment, A and A^1 each represent N. In another embodiment, A represents N and A^1 represents CH.

In one embodiment, B represents N. In another embodiment, B represents CH.

In one embodiment, R¹ represents cyclopropyl; R² represents methyl or ethyl; A and A¹ each represent N; and B represents CH.

5 In one embodiment, R¹ represents cyclopropyl; R² represents methyl or ethyl; A and A¹ each represent N; and B represents N.

In one embodiment, R¹ represents cyclopropyl; R² represents methyl or ethyl; A represents N and A¹ represents CH; and B represents N.

10

In one embodiment, R¹ represents cyclopropyl; R² represents methyl or ethyl; A represents N and A¹ represents CH; and B represents CH.

15


In one embodiment, R¹ represents cyclopropyl; said cyclopropyl group being optionally further substituted by CH₃, CN or one or two fluoro atoms; R² represents C1 to 3 alkyl; and A, A¹ and B independently represent CH or N.

20

Unless otherwise indicated, the term "C1 to 3 alkyl" referred to herein denotes a straight or branched chain alkyl group having from 1 to 3 carbon atoms. Examples of such groups include methyl, ethyl, n-propyl and i-propyl.

Examples of a cyclopropyl ring optionally further substituted by one or two fluoro atoms include 1-fluoro-1-cyclopropyl, 2,2-difluoro-1-cyclopropyl and 2,3-difluoro-1-cyclopropyl:

25



Examples of compounds of the invention include:

(5*S*)-5-({[6-(2-cyclopropylpyrimidin-5-yl)-3,4-dihydroisoquinolin-2(1*H*)-
yl]sulfonyl}methyl)-5-methylimidazolidine-2,4-dione;

5 (5*S*)-5-({[6-(6-cyclopropylpyridin-3-yl)-3,4-dihydro-2,7-naphthyridin-2(1*H*)-
yl]sulfonyl}methyl)-5-methylimidazolidine-2,4-dione;

(5*S*)-5-({[6-(2-cyclopropylpyrimidin-5-yl)-3,4-dihydro-2,7-naphthyridin-2(1*H*)-
yl]sulfonyl}methyl)-5-methylimidazolidine-2,4-dione;

(5*S*)-5-({[6-(2-cyclopropylpyrimidin-5-yl)-3,4-dihydro-2,7-naphthyridin-2(1*H*)-
yl]sulfonyl}methyl)-5-ethylimidazolidine-2,4-dione;

(5*S*)-5-({[6-(2-cyclopropylpyrimidin-5-yl)-3,4-dihydroisoquinolin-2(1*H*)-
yl]sulfonyl}methyl)-5-ethylimidazolidine-2,4-dione;

(5*S*)-5-({[6-(2-cyclobutylpyrimidin-5-yl)-3,4-dihydroisoquinolin-2(1*H*)-
yl]sulfonyl}methyl)-5-methylimidazolidine-2,4-dione;

15 (5*S*)-5-methyl-5-({[6-[2-(1-methylcyclopropyl)pyrimidin-5-yl]-3,4-dihydroisoquinolin-
2(1*H*)-yl]sulfonyl}methyl)imidazolidine-2,4-dione;

(5*S*)-5-Cyclopropyl-5-({[6-(2-cyclopropylpyrimidin-5-yl)-3,4-dihydroisoquinolin-2(1*H*)-
yl]sulfonyl}methyl)imidazolidine-2,4-dione;

and pharmaceutically acceptable salts thereof.

20

Each exemplified compound represents a particular and independent aspect of the invention.


The compounds of formula (I) may exist in enantiomeric forms. Therefore, all enantiomers,
25 diastereomers, racemates and mixtures thereof are included within the scope of the invention.

The various optical isomers may be isolated by separation of a racemic mixture of the compounds using conventional techniques, for example, fractional crystallisation, or HPLC. Alternatively the optical isomers may be obtained by asymmetric synthesis, or by synthesis from optically active starting materials.

30

Where optically isomers exist in the compounds of the invention, we disclose all individual optically active forms and combinations of these as individual specific embodiments of the invention, as well as their corresponding racemates.

5 Preferably the compounds of formula (I) have (5S)-stereochemistry as shown below:



10 Where tautomers exist in the compounds of the invention, we disclose all individual tautomeric forms and combinations of these as individual specific embodiments of the invention.

15 The present invention includes compounds of formula (I) in the form of salts. Suitable salts include those formed with organic or inorganic acids or organic or inorganic bases. Such salts will normally be pharmaceutically acceptable salts although non-pharmaceutically acceptable salts may be of utility in the preparation and purification of particular compounds. Such salts include acid addition salts such as hydrochloride, hydrobromide, citrate, tosylate and maleate salts and salts formed with phosphoric acid or sulphuric acid. In another aspect suitable salts are base salts such as an alkali metal salt, for example, sodium or potassium, an alkaline earth metal salt, for example, calcium or magnesium, or 20 an organic amine salt, for example, triethylamine.

Salts of compounds of formula (I) may be formed by reacting the free base or another salt thereof with one or more equivalents of an appropriate acid or base.

25

The compounds of formula (I) are useful because they possess pharmacological activity in animals and are thus potentially useful as pharmaceuticals. In particular, the compounds of

the invention are metalloproteinase inhibitors and may thus be used in the treatment of diseases or conditions mediated by MMP12 and/or MMP9 such as asthma, rhinitis, chronic obstructive pulmonary diseases (COPD), arthritis (such as rheumatoid arthritis and osteoarthritis), atherosclerosis and restenosis, cancer, invasion and metastasis, diseases involving tissue destruction, loosening of hip joint replacements, periodontal disease, fibrotic disease, infarction and heart disease, liver and renal fibrosis, endometriosis, diseases related to the weakening of the extracellular matrix, heart failure, aortic aneurysms, CNS related diseases such as Alzheimer's disease and multiple sclerosis (MS), and haematological disorders.

10

In general, the compounds of the present invention are potent inhibitors of MMP9 and MMP12. The compounds of the present invention also show good selectivity with respect to a relative lack of inhibition of various other MMPs such as MMP8, MMP14 and MMP19.

15

Accordingly, the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, as hereinbefore defined for use in therapy.

20

In another aspect, the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.

25

In another aspect, the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as hereinbefore defined in the manufacture of a medicament for use in the treatment of diseases or conditions in which inhibition of MMP12 and/or MMP9 is beneficial.

30

In another aspect, the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as hereinbefore defined in the manufacture of a medicament for use in the treatment of inflammatory disease.

In another aspect, the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as hereinbefore defined in the manufacture of a medicament for use in the treatment of an obstructive airways disease such as asthma or COPD.

5

In another aspect, the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as hereinbefore defined in the manufacture of a medicament for use in the treatment of rheumatoid arthritis, osteoarthritis, atherosclerosis, cancer or multiple sclerosis.

10

In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

15 Prophylaxis is expected to be particularly relevant to the treatment of persons who have suffered a previous episode of, or are otherwise considered to be at increased risk of, the disease or condition in question. Persons at risk of developing a particular disease or condition generally include those having a family history of the disease or condition, or those who have been identified by genetic testing or screening to be particularly
20 susceptible to developing the disease or condition.

The invention further provides a method of treating a disease or condition in which inhibition of MMP12 and/or MMP9 is beneficial which comprises administering to a patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined.

25 The invention also provides a method of treating an obstructive airways disease, for example, asthma or COPD, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined.

30

For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder to be treated. The daily dosage of the compound of formula (I)/salt (active ingredient) may be in the range from 0.001 mg/kg to 75 mg/kg, in particular from 0.5 mg/kg to 30 mg/kg. This daily dose may be given in divided doses as necessary. 5 Typically unit dosage forms will contain about 1 mg to 500 mg of a compound of this invention.

The compounds of formula (I) and pharmaceutically acceptable salts thereof may be used 10 on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.10 to 70 %w, of active ingredient, and, 15 from 1 to 99.95 %w, more preferably from 30 to 99.90 %w, of a pharmaceutically acceptable adjuvant, diluent or carrier, all percentages by weight being based on total composition. Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, "Pharmaceuticals - The Science of Dosage Form Designs", M. E. Aulton, Churchill Livingstone, 1988.

20 Thus, the present invention also provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

25 The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined with a pharmaceutically acceptable adjuvant, diluent or carrier.


30 The pharmaceutical compositions of this invention may be administered in a standard manner for the disease or condition that it is desired to treat, for example by oral, topical, parenteral, buccal, nasal, vaginal or rectal administration or by inhalation. For these

purposes the compounds of this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions, suspensions, emulsions, creams, ointments, gels, nasal sprays, suppositories, finely divided powders or aerosols for inhalation, and for parenteral use (including intravenous, intramuscular or infusion) sterile aqueous or oily solutions or suspensions or sterile emulsions.


In addition to the compounds of the present invention the pharmaceutical composition of this invention may also contain, or be co-administered (simultaneously or sequentially) with, one or more pharmacological agents of value in treating one or more diseases or 10 conditions referred to hereinabove such as "Symbicort" (trade mark) product.

The present invention further provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined above which, comprises:

15 a) reaction of a compound of formula (II)




wherein R² is as defined in formula (I) and L¹ represents a leaving group, with a 20 compound of formula (III) (or a salt thereof)



(III)

wherein R^1 , A, A^1 and B are as defined in formula (I); or


b) reaction of a compound of formula (V)



(V)

5.

wherein R^2 and B are as defined in formula (I) and LG is a leaving group; with a boronic acid derivative of formula (XII)




(XII)

10

wherein R^1 , A and A^1 are as defined in formula (I); or

c) reaction of a compound of formula (IX)



wherein R^1 , R^2 , A, A^1 and B are as defined in formula (I); with ammonium carbonate and potassium cyanide;


and optionally thereafter forming a pharmaceutically acceptable salt thereof.

- 5 In the above process (a), suitable leaving groups L^1 include halo, particularly chloro or trifluoromethylsulfonate. The reaction is preferably performed in a suitable solvent optionally in the presence of an added base for a suitable period of time, typically 0.5 to 16 h, at ambient to reflux temperature. Typically solvents such as N,N-dimethylformamide, pyridine, tetrahydrofuran, acetonitrile, N-methylpyrrolidine or dichloromethane are used.
- 10 When used, the added base may be an organic base such as triethylamine, N,N-diisopropylethylamine, N-methylmorpholine or pyridine, or an inorganic base such as an alkali metal carbonate. The reaction is typically conducted at ambient temperature for 0.5 to 16 h, or until completion of the reaction has been achieved, as determined by chromatographic or spectroscopic methods. Reactions of sulfonyl halides with various
- 15 primary and secondary amines are well known in the literature, and the variations of the conditions will be evident for those skilled in the art.

Sulfonylchlorides of formula (II) wherein L^1 represents chloro and R^2 represents Me are disclosed in WO 02/074767 and references cited therein. Corresponding compounds
20 wherein R^2 represents C1 to 3 alkyl may be prepared using analogous methods.

Suitable processes for the preparation of compounds of formula (I) are described in a retrosynthetic way in Scheme 1.

Scheme 1



In Scheme 1, protecting groups (PG) can be either carbamates (e.g. *tert*-butoxycarbamate), amides (e.g. trifluoroacetyl) or alkyl (e.g. *tert*-butyl or benzyl). Leaving groups (LG) can be either chloride, bromide, iodide or trifluoromethylsulfonate. In the palladium-catalysed Suzuki couplings, either boronic acids or pinacolboronates may be used. Intermediate (IVa-c) can be prepared by standard Suzuki coupling (*Chem. Rev.* **1995**, *95*, 2457) between an electrophile (VIIa-c) and a boron reagent (XII), or the other way around, between an electrophile (XI) and a boron reagent (VIIa-c). The latter can be obtained from (VIIa-c) using standard Miyaura conditions (*J. Org. Chem.* **1995**, *60*, 7508-7510). Deprotection of (IVa-c) either by hydrogen chloride in methanol (PG = *tert*-butoxycarbonyl) or refluxing 1-chloroethyl chloroformate/ refluxing methanol (PG = *tert*-butyl or benzyl) (*Synlett.* **1993**, 195-196) gives amine (IIIa-c) as a hydrochloride salt. The free base can be obtained by treatment of (IIIa-c) with base and extraction with an organic solvent such as ethyl acetate or toluene. Reacting (IIIa-c) either as a salt or base in a suitable solvent (e.g. acetonitrile,

tetrahydrofuran, *N*-methylpyrrolidine or *N,N*-dimethylformamide) with the sulfonyl chloride (II) in the presence of a tertiary amine (e.g. triethylamine, pyridine or *N,N*-diisopropylethylamine) for 0.5 to 16 hours produces compounds of formula (I).

- 5 An alternative route to compounds of formula (I) from intermediate (IIIa-c) via methanesulfonamide (Xa-c) and ketone (IXa-c) has been previously described (WO 02/074767). Briefly, treatment of (IIIa-c) with methansulfonyl chloride and a tertiary amine (e.g. triethylamine, pyridine or *N,N*-diisopropylethylamine) in a suitable solvent (e.g. dichloromethane or tetrahydrofuran) produces the methansulfonamide (Xa-c) which in turn can be transformed into the ketone (IXa-c) using standard procedures. Heating ketone (IXa-c) with ammonium carbonate and potassium cyanide in 50% aqueous ethanol in a sealed vial at 80-90 °C for 1 to 5 hours gives a racemic hydantoin that can be resolved by chiral chromatography (e.g. on OD-H with 100% ethanol).
- 10
- 15 In a third route, intermediate (VIIa-c) is deprotected as described above to give amine (VIa-c) as a hydrochloride salt. The free base can be isolated by treatment with base and extraction with an organic solvent e.g. ethyl acetate or toluene. Reacting (VIa-c) either as a salt or base in a suitable solvent (e.g. acetonitrile, tetrahydrofuran, *N*-methylpyrrolidine or *N,N*-dimethylformamide) with sulfonyl chloride (II) in the presence of a tertiary amine (e.g. triethylamine, pyridine or *N,N*-diisopropylethylamine) for 0.5 to 16 hours produces chiral sulfonamide (Va-c). The latter can be coupled with boron reagent (XII) using standard Suzuki conditions to give compounds of formula (I).
- 20

Intermediates (VIIa-b) are conveniently prepared using the following methods.

25

The 1,2,3,4-tetrahydroisoquinoline intermediate (VIIa)


Methods for the synthesis of 1,2,3,4-tetrahydroisoquinolines are well known in the literature. The classical route is the Pomeranz-Fritz reaction of benzaldehydes with a diacetal protected aminoacetaldehyde (*Org. React.* **1951**, 6, 191) yielding the isoquinoline nucleus which upon catalytical reduction gives 1,2,3,4-tetrahydro-isoquinolines. Another route is the Bischler-Napieralski reaction (*Org. React.* **1951**, 6, 74) of a carbamate of

30

2-phenylethanamines with phosphoryl chloride in refluxing toluene or xylenes. Reduction of the resulting cyclic benzamide with lithium aluminium hydride in tetrahydrofuran (*J. Med. Chem.* **1987**, *30*(12), 2208-2216) or diborane in tetrahydrofuran (*J. Med. Chem.* **1980**, *23*(5), 506-511) affords the 1,2,3,4-tetrahydroisoquinoline. A variation of the 5 Bischler-Napieralski reaction is the Pictet-Spengler synthesis (*Org. React.* **1951**, *6*, 151). In this reaction amides, carbamates or sulfonamides of 2-phenylethanamines are heated with paraformaldehyde and strong proton acids (e.g. trifluoroacetic acid, sulfuric acid) or Lewis acids in a solvent (e.g. dichloromethane, toluene, formic acid) to give the 1,2,3,4-tetrahydroisoquinoline in a single step (*Tetrahedron* **2002**, *58*(8), 1471-1478).

10

Scheme 2



Reagents:

- a) $(CF_3CO)_2O$, Et_3N ; $+4^\circ C$.
- b) $(HCHO)_n$, H_2SO_4 , $HOAc$; RT.
- c) $NaBH_4$, $EtOH$; RT or NH_3 (conc), $EtOH$, heat.
- d) $(t-BuOCO)_2O$, Et_3N , DCM, RT.

Preferably the 1,2,3,4-tetrahydroisoquinoline intermediate (VIIa) is synthesised by Route A shown in Scheme 2. This route is a Friedel-Crafts-type reaction of *N*-[2-(3-bromophenyl)ethyl]-2,2,2-trifluoroacetamide with formaldehyde and sulfuric acid in acetic acid (*Tetrahedron Lett.* **1996**, *37*(31), 5453-5456) giving a mixture of the 6-bromo- and 8-bromo isomer in a ratio of 3 to 1. Replacement of the trifluoroacetamide group with a BOC-group gives (VIIa). The regioisomers are not conveniently separated at this stage.

20


The 1,2,3,4-tetrahydro-2,7-naphthyridine intermediate (VIIb)

In contrast to the 1,2,3,4-tetrahydroisoquinolines, there are rather few examples of synthetic methods for 1,2,3,4-tetrahydro-2,7-naphthyridines in the literature. One important method to prepare 1,2,3,4-tetrahydro-2,7-naphthyridine is the regio-selective catalytic reduction of 2,7-naphthyridine (*Eur. J. Med. Chem. Ther.* **1996**, *31*(11), 875-888). 25 The synthesis of 2,7-naphthyridine and some derivatives thereof has been described in the

literature. One classical route involves several steps and starts with the acid catalysed condensation of malononitrile with diethyl 1,3-acetonedicarboxylate (*J. Chem. Soc.* **1960**, 3513-3515; see also *J. Heterocycl. Chem.* **1970**, 7, 419-421). A slightly different route to 2,7-naphthyridine involves oxidation of 4-formyl-2,7-naphthyridine to give 5 2,7-naphthyridine-4-carboxylic acid followed by decarboxylation (*Synthesis* **1973**, 46-47). A completely different method is based on the internal Diels-Alder reaction of *N*-(ethoxycarbonyl)-*N*-(but-3-ynyl)amino-methylpyrazine and gives a mixture of 1,2,3,4-tetrahydro-2,7-naphthyridine and 5,6,7,8-tetrahydro-1,7-naphthyridine after hydrolysis of the carbamate group (WO 02/064574).

10

Scheme 3



Reagents:


a) $\text{LiCH}_3\text{NCH}_2\text{CH}_2\text{N}(\text{CH}_3)_2$, THF, -70°C . b) $n\text{-BuLi}$ in hexanes, -70°C , then I_2 . c) TMS-acetylene, $\text{PdCl}_2(\text{PPh}_3)_2$, CuI , Et_3N , THF, 60°C .
 d) 7 M NH_3 , EtOH , 80°C . e) H_2 , PtO_2 , HOAc . f) 48% HBr (aq), 120°C . g) $(\text{BOC})_2\text{O}$, Et_3N , H_2O , THF. h) Tf_2O , PhMe , 30% K_3PO_4 .

Preferably the 1,2,3,4-tetrahydro-2,7-naphthyridine intermediate (VIIb) can be synthesised as shown in Schemes 3 and 4. In Route B, commercially available 15 6-methoxynicotinaldehyde is treated successively with the lithium salt of *N,N,N'*-trimethylethylenediamine, then *n*-BuLi in hexanes and finally iodine to afford the 4-iodo-6-methoxynicotinaldehyde (cf. *Tetrahedron Lett.* **1993**, 34(39), 6173-6176). The iodo compound is coupled with trimethylsilylacetylene under usual Sonagashira-Hagiwara conditions (*Synthesis* **1980**, 627-630) and the resulting 6-methoxy-4-20 [(trimethylsilyl)ethynyl]nicotinaldehyde is condensed with ammonium hydroxide in ethanol to give 3-methoxy-2,7-naphthyridine (*Synthesis* **1999**, 2, 306-311). Regioselective catalytic reduction (cf. *Eur. J. Med. Chem. Ther.* **1996**, 31(11), 875-888) affords

6-methoxy-1,2,3,4-tetrahydro-2,7-naphthyridine. Demethylation and N-protection with BOC-anhydride and finally treatment of the resulting *tert*-butyl 6-hydroxy-3,4-dihydro-2,7-naphthyridine-2(1*H*)-carboxylate with triflic anhydride in a two-phase system gives (VIIb).

5

Scheme 4



Reagents:
a) n-BuLi, THF, -70°C then DMF, -70°C to RT. b) t-BuNH₂, DCM, 3 Å mol. sieves. c) Li-TMP, -20°C then DMF, -20 to -10°C.
d) NaBH₃CN, MeOH, HOAc; RT. e) 48% HBr (aq), reflux; work-up with K₂CO₃ (aq). f) Tf₂O, pyridine +4°C.

In Route C, commercially available 5-bromo-2-methoxy-4-methylpyridine in anhydrous tetrahydrofuran is metallated with *n*-BuLi and then treated with *N,N*-dimethylformamide to afford 6-methoxy-4-methylnicotinaldehyde. This was converted to the *tert*-butylimine with *tert*-butylamine in dichloromethane. Metallation with lithium 2,2,6,6-tetramethylpiperidide (Li-TMP) (cf. *J. Org. Chem.* 1993, 58, 2463-2467) and addition of *N,N*-dimethylformamide affords the iminoacetaldehyde which is reduced with sodium cyanoborohydride in methanol to give 2-*tert*-butyl-6-methoxy-1,2,3,4-tetrahydro-2,7-naphthyridine. Cleavage of the methyl group with refluxing 48% hydrobromic acid and treatment with triflic anhydride in the presence of base gives (VIIb) protected as the *tert*-butylamine.

It will be appreciated by those skilled in the art that in the processes of the present invention certain potentially reactive functional groups such as hydroxyl or amino groups in the starting reagents or intermediate compounds may need to be protected by suitable

protecting groups. Thus, the preparation of the compounds of the invention may involve, at various stages, the addition and removal of one or more protecting groups.

5 Suitable protecting groups and details of processes for adding and removing such groups are described in 'Protective Groups in Organic Chemistry', edited by J.W.F. McOmie, Plenum Press (1973) and 'Protective Groups in Organic Synthesis', 3rd edition, T.W. Greene and P.G.M. Wuts, Wiley-Interscience (1999).

10 The compounds of the invention and intermediates thereto may be isolated from their reaction mixtures and, if necessary further purified, by using standard techniques.

The present invention will now be further explained by reference to the following illustrative examples.

15 General Methods

¹H NMR and ¹³C NMR spectra were recorded on a Varian *Inova* 400 MHz or a Varian *Mercury*-VX 300 MHz instrument. The central peaks of chloroform-*d* (δ_{H} 7.27 ppm), dimethylsulfoxide-*d*₆ (δ_{H} 2.50 ppm), acetonitrile-*d*₃ (δ_{H} 1.95 ppm) or methanol-*d*₄ (δ_{H} 3.31 ppm) were used as internal references. Column chromatography was carried out using 20 silica gel (0.040-0.063 mm, Merck) with a slight over-pressure (0.2-0.4 bars) applied on the column. A Kromasil KR-100-5-C₁₈ column (250 × 20 mm, Akzo Nobel) and mixtures of acetonitrile/water with 0.1 % TFA at a flow rate of 10 mL/min were used for preparative HPLC. Unless stated otherwise, starting materials were commercially available. All 25 solvents and commercial reagents were of laboratory grade and were used as received. The organic phases from extractions were dried over anhydrous sodium sulfate if not stated otherwise. Organic phases or solutions were concentrated by rotary evaporation. Yields were not optimised.

The following method was used for LC-MS analysis:

30 Instrument *Agilent 1100*; Column *Waters Symmetry* 2.1 × 30 mm; Mass APCI; Flow rate 0.7 mL/min; Wavelength 254 or 220 nm; Solvent A: water + 0.1% TFA; Solvent B: acetonitrile + 0.1% TFA ; Gradient 15-95% /B 2.7 min, 95% B 0.3 min.


The following method was used for GC-MS analysis:

Instrument *Hewlett Packard 5890 Series II*; Column *Agilent HP-5* (30 m x 0.32 mm ID);
Mass selective detector *Hewlett Packard 5971 Series*; Pressure 55 kPa He; Oven program
5 100°C (3 min) to 300°C, 25°C/ min.

Abbreviations:

	BOC-anhydride	di- <i>tert</i> -butyl dicarbonate
10	<i>n</i> -BuLi	<i>n</i> -butyl lithium
	DCM	dichloromethane
	DIPEA	<i>N,N</i> -diisopropylethylamine
	DMF	<i>N,N</i> -dimethylformamide
	DMSO	dimethylsulfoxide
15	EtOAc	ethyl acetate
	EtOH	ethanol
	GC-MS	gas chromatography- mass spectrometry
	LDA	lithium diisopropylamide
	MeOH	methanol
20	LC-MS	liquid chromatography- mass spectroscopy
	PdCl ₂ x dppf	1,1'-bis(diphenylphosphino)ferrocene palladium(II)dichloride
	RT	room temperature, normally 20 to 22 °C
	TEA	triethylamine
	THF	tetrahydrofuran
25	TBME	<i>tert</i> -butyl methyl ether
	TFA	trifluoroacetic acid
	Triflic anhydride	trifluoromethanesulfonic anhydride (Tf ₂ O)

Example 1 (5*S*)-5-({[6-(2-Cyclopropylpyrimidin-5-yl)-3,4-dihydroisoquinolin-2(1*H*)-
30 yl]sulfonyl}methyl)-5-methylimidazolidine-2,4-dione



[(4S)-4-Methyl-2,5-dioxoimidazolidin-4-yl]methanesulfonyl chloride (0.020 g, 0.087 mmol) in anhydrous THF (0.40 mL) was added dropwise to a stirred solution of 5 6-[2-(cyclopropyl)pyrimidin-5-yl]-1,2,3,4-tetrahydroisoquinoline (0.023 g, 0.091 mmol), DIPEA (0.022 mL, 0.13 mmol) and dry THF (0.50 mL) at RT. After the addition was complete, the solution was stirred at RT for 2 h and then taken up in water-brine and extracted twice with EtOAc. The combined organic phases were washed with brine, dried, filtered and concentrated to give a crude product. Purification by preparative HPLC 10 afforded 0.021 g (50%) of the title compound as a white solid.

LC-MS *m/z* 442 (M+1);

¹H NMR (CD₃CN) δ 8.97 (s, 2H), 8.62 (br s, 1H), 7.52 (s, 1H), 7.51 (dd, 1H), 7.30 (d, 1H), 6.40 (br s, 1H), 4.48 (s, 2H), 3.54 (t, 2H), 3.51 (d, 1H), 3.42 (d, 1H), 3.01 (t, 2H), 2.38 (m, 1H), 1.48 (s, 3H) and 1.23 (m, 4H) ppm.

15

The starting materials were prepared as follows:

6-[2-(Cyclopropyl)pyrimidin-5-yl]-1,2,3,4-tetrahydroisoquinoline

20 *tert*-Butyl 6-[2-(cyclopropyl)pyrimidin-5-yl]-3,4-dihydroisoquinoline-2(1*H*)-carboxylate (0.034 g, 0.13 mmol) was stirred in TFA (1.0 mL) and DCM (1.0 mL) at RT overnight, then concentrated twice, the second time with added toluene (5 mL), to afford the trifluoroacetate of the title product.

¹H NMR (CD₃OD) δ 8.87 (s, 2H), 7.60 (d, 1H), 7.59 (s, 1H), 7.37 (d, 1H), 4.43 (s, 2H), 3.55 (t, 2H), 3.21 (t, 2H), 2.27 (m, 1H), and 1.14 (m, 4H) ppm.

25 The crude product was taken up in 1M sodium carbonate solution (10 mL) and extracted twice with EtOAc. The combined organic phases were washed with brine, dried, filtered and concentrated to give 0.023 g (94%) of the title product as a white solid.

LC-MS *m/z* 252 (M+1).

5-Bromo-2-cyclopropylpyrimidine

The title compound was prepared according to Hickey et al. (WO 00/066566).

LC-MS *m/z* 199/201 (M+1);

5 ^1H NMR (CDCl₃) δ 8.61 (s, 2H), 2.30-2.18 (m, 1H) and 1.15-1.10 (m, 4H) ppm.

tert-Butyl 6-[2-(cyclopropyl)pyrimidin-5-yl]-3,4-dihydroisoquinoline-2(1*H*)-carboxylate

A 4:1 mixture (0.097 g, 0.27 mmol) of *tert*-butyl 6-(4,4,5,5-tetramethyl-1,3,2-

10 dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1*H*)-carboxylate and *tert*-butyl 8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1*H*)-carboxylate, 5-bromo-2-cyclopropylpyrimidine (0.054 g, 0.27 mmol), PdCl₂ x dppf (0.0045 g), 2M sodium carbonate (1.0 mL), toluene (4.0 mL) and EtOH (1.0 mL) was purged with dry argon for ten minutes, then heated in a sealed vial at 81 °C for 6 h. The black solution was 15 filtered through glass-wool, taken up in water-brine and washed twice with EtOAc. The combined organic phases were dried, filtered and concentrated with silica (5 g). Column chromatography with EtOAc-heptanes (1:5 through 1:2) gave 0.034 g (36%) of the title product as white solid.

LC-MS *m/z* 352 (M+1);

20 ^1H NMR (CDCl₃) δ 8.74 (s, 2H), 7.35 (dd, 1H), 7.29 (s, 1H), 7.22 (d, 1H), 4.62 (s, 2H), 3.68 (t, 2H), 2.90 (t, 2H), 2.30 (m, 1H), 1.50 (s, 9H), 1.18 (m, 2H) and 1.11 (m, 2H) ppm.

tert-Butyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1*H*)-carboxylate

25 A 3:1 mixture (0.49 g, 1.6 mmol) of *tert*-butyl 6-bromo-3,4-dihydroisoquinoline-2(1*H*)-carboxylate and *tert*-butyl 8-bromo-3,4-dihydroisoquinoline-2(1*H*)-carboxylate, bis(pinacolato)diborane (0.45 g, 1.8 mmol), PdCl₂ x dppf (0.039 g, 0.048 mmol), potassium acetate (0.48 g, 4.8 mmol) and DMF (8.0 mL) was heated at 81 °C overnight. The solvent was evaporated, the residue taken up in water-brine and washed twice with EtOAc. The organic phase was dried, filtered and concentrated. Column chromatography with EtOAc-heptanes (1:10 through 1:4) gave 0.24 g of a 4:1 mixture of

the title product and *tert*-butyl 8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1*H*)-carboxylate.

¹H NMR (CDCl₃) δ 7.62 (d, 1H), 7.60 (s, 1H), 7.13 (d, 1H), 4.59 (s, 2H), 3.64 (t, 2H), 2.85 (t, 2H), 1.50 (s, 9H) and 1.35 (s, 12H) ppm (6-isomer).

¹H NMR (CDCl₃) δ 7.69 (d, 1H), 7.24-7.14 (m's, 2H), 4.88 (s, 2H), 3.64 (t, 2H), 2.85 (t, 2H), 1.50 (s, 9H) and 1.35 (s, 12H) ppm (8-isomer).

tert-Butyl 6-bromo-3,4-dihydroisoquinoline-2(1*H*)-carboxylate

6-Bromo-2-(trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline was prepared in two steps from [2-(3-bromophenyl)ethyl]amine (4.0 g, 20 mmol) following the procedure of Stokker (*Tetrahedron Lett.* **1996**, *37*(31), 5453-5456). Column chromatography with EtOAc-heptanes (1:10 through 1:6) gave 2.3 g (7.5 mmol) of a 3:1 mixture of 6-bromo-2-(trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline and 8-bromo-2-(trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline.

¹H NMR (CDCl₃) δ 7.62 (d, 1H), 7.60 (s, 1H), 7.13 (d, 1H), 4.59 (s, 2H), 3.64 (t, 2H), 2.85 (t, 2H) and 1.50 (s, 9H) and 1.35 (s, 12H) ppm (6-isomer).

¹H NMR (CDCl₃) δ 7.69 (d, 1H), 7.24-7.14 (m, 2H), 4.88 (s, 2H), 3.64 (t, 2H), 2.85 (t, 2H) and 1.50 (s, 9H) and 1.35 (s, 12H) ppm (8-isomer).

This mixture was stirred with absolute EtOH (100 mL) and 25% ammonium hydroxide (10 mL) at 60 °C for 4 h. More 25% ammonium hydroxide (15 mL) was added and stirring continued at RT overnight. The volatiles were evaporated to leave the crude amine as a white solid. LC-MS *m/z* 212/214 (M+1).

Dry THF (50 mL) and DIPEA (1.3 mL, 7.5 mmol) were added followed by BOC-anhydride (1.8 g, 8.2 mmol). The mixture was stirred overnight at RT. The volatiles were evaporated and the residue was taken up in water. The pH was adjusted to 2 with 1M phosphoric acid and the product was extracted twice with EtOAc. The combined organic phases were washed with brine made slightly alkaline with saturated sodium bicarbonate, dried, filtered and concentrated. The crude product was purified by column chromatography with EtOAc-heptanes (1:50 through 1:20) to give 2.24 g (96%) of a 3:1 mixture of the title product and *tert*-butyl 8-bromo-3,4-dihydroisoquinoline-2(1*H*)-carboxylate.

LC-MS *m/z* 256/258 (M-56);

¹H NMR (CDCl₃) δ 7.31 (dd, 1H), 7.30 (br s, 1H), 6.98 (d, 1H), 4.52 (s, 2H), 3.63 (t, 2H),

2.81 (t, 2H) and 1.50 (s, 9H) ppm (6-isomer).

¹H NMR (CDCl₃) δ 7.42 (dd, 1H), 7.12-7.01 (m's, 2H), 4.55 (s, 2H), 3.64 (t, 2H), 2.84 (t,

5 2H) and 1.51 (s, 9H) ppm (8-isomer).

Alternatively, 6-(2-cyclopropyl-pyrimidin-5-yl)-1,2,3,4-tetrahydro-isoquinoline may be prepared as follows:

10 a) 1,2,3,4-Tetrahydro-isoquinolin-6-ol hydrobromide


6-Methoxy-1,2,3,4-tetrahydro-isoquinoline hydrochloride, prepared as in WO 2004/26305, (18.9 g, 94 mmol) in 48% aqueous hydrobromic acid was heated at 100 °C for 12 h and then cooled to 0 °C. The solid was filtered off, washed with t-butyl methyl ether and dried.

Yield = 17.1 g (79%)

15 APCI-MS *m/z*: 150 [M+H⁺];

¹H NMR (400 MHz, DMSO-d₆) δ 2.91 (t, 2H), 3.27 - 3.35 (m, 2H), 4.13 (t, 2H), 4.52 (s, 1H), 6.59 (d, 1H), 6.66 (dd, 1H), 7.00 (d, 1H), 9.07 (s, 2H) ppm.

20 b) 6-Trifluoromethanesulfonyloxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester



The above two steps were performed as described in Synthetic Communications, 25(20), 3255-3261, (1995).

c) 6-(2-Cyclopropyl-pyrimidin-5-yl)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester

6-Trifluoromethanesulfonyloxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester (11.51 g, 30 mmol) was dissolved in DMF (250 mL) and the yellow solution was purged by bubbling argon (g) through the solution. Potassium acetate (8.83 g, 90 mmol), bis(pinacolato)diboron (8.38 g, 33 mmol), PdCl₂dppf (1.22 g, 1.5 mmol) and dppf (0.83 g, 1.5 mmol) were added and the mixture was purged again with argon. The mixture was then heated to 90 °C for 2 h. Tripotassium phosphate monohydrate (18 g, 78 mmol) was added followed by 2-cyclopropyl-5-bromo-pyrimidine (7.76 g, 39 mmol) and stirring was continued for 5 h at 90 °C. The reaction mixture was poured onto saturated sodium bicarbonate solution and extracted several times with ethyl acetate. The ethyl acetate solution was dried over magnesium sulphate, the drying agent filtered off and the filtrate was evaporated. The residue was purified by flash chromatography eluting with ethyl acetate : heptane (1:3) to give 8.1 g (76%) of the title compound as a colourless solid.

APCI-MS m/z: 352 [M+H⁺];

¹H-NMR(CDCl₃): δ 8.77 (2H, s), 7.36 (1H, d), 7.31 (1H, brs), 7.24 (1H, d), 4.63 (2H, s), 3.70 (2H, brt), 2.92 (2H, brt), 2.35 (1H, m), 1.51 (9H, s), 1.24-1.10 (4H, m) ppm.

d) 6-(2-Cyclopropyl-pyrimidin-5-yl)-1,2,3,4-tetrahydro-isoquinoline

6-(2-Cyclopropyl-pyrimidin-5-yl)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester (9.49 g, 27 mmol) was dissolved in ethyl acetate (100 mL) at 50 °C, and to this warm solution was added 1.5M hydrogen chloride in ethyl acetate (200 mL). After 1 h, the mixture was cooled to room temperature and the solid was filtered off and dried.

APCI-MS m/z: 252 [M+H⁺];

¹H-NMR(CD₃OD): δ 9.35 (2H, s), 7.76-7.70 (2H, brs+brdd), 7.46 (1H, d), 4.47 (2H, s), 3.57 (2H, t), 3.25 (2H, t), 2.46 (1H, m), 1.51-1.45 (4H, m) ppm.

¹³C-NMR(CD₃OD): δ 168.39, 155.82, 134.34, 132.65, 132.52, 131.32, 129.22, 128.74, 126.69, 45.56, 42.69, 26.17, 16.51, 14.11 ppm.


The dihydrochloride salt (8.82 g, 27 mmol) was suspended in water (100 mL) and 2M NaOH (300 mL) was added. The mixture was then extracted with 4:1 ethyl acetate / diethyl

ether (4 x 300 mL). The combined organic phases were dried over anhydrous potassium carbonate, filtered and evaporated to give the title compound as the free base (6.65 g).

APCI-MS m/z: 252 [M+H⁺];

¹H-NMR(CD₃OD): δ 8.81 (2H, s), 7.43-7.38 (2H, d+s), 7.18 (1H, d), 3.99 (2H, s), 3.10 (2H, t), 2.90 (2H, t), 2.25 (1H, m), 1.18-1.06 (4H, m) ppm.
¹³C-NMR(CD₃OD): δ 171.53, 155.83, 137.05, 137.01, 133.50, 132.32, 128.51, 128.36, 125.20, 48.35, 44.28, 29.49, 18.38, 11.16 ppm.

10 **Example 2 (5S)-5-({[6-(6-Cyclopropylpyridin-3-yl)-3,4-dihydro-2,7-naphthyridin-2(1H)-yl]sulfonyl}methyl)-5-methylimidazolidine-2,4-dione**



15 The title compound was prepared from 6-(6-cyclopropylpyridin-3-yl)-1,2,3,4-tetrahydro-2,7-naphthyridine hydrochloride (0.63 mmol) and [(4S)-4-methyl-2,5-dioxoimidazolidin-4-yl]methanesulfonyl chloride (0.70 mmol) following the general procedure of Example 1. Column chromatography with neat EtOAc and EtOAc-MeOH (9:1) as eluents gave 0.060 g of almost pure product. Recrystallisation from 99% EtOH gave 0.019 g (7.0 %) of the title compound as white solid.

20 LC-MS m/z 442 (M+1);

¹H NMR (DMSO-d₆) δ 10.8 (s, 1H), 9.06 (d, 1H), 8.49 (s, 1H), 8.26 (dd, 1H), 8.06 (s, 1H), 7.83 (s, 1H), 7.39 (d, 1H), 4.45 (s, 2H), 3.61 (d, 1H), 3.48 (d, 1H), 3.46 (m, 2H), 2.97 (m, 2H), 2.16 (m, 1H), 1.34 (s, 3H) and 1.02-0.94 (m, 4H) ppm.

25

The starting materials were prepared as follows:

6-(6-Cyclopropylpyridin-3-yl)-1,2,3,4-tetrahydro-2,7-naphthyridine hydrochloride

5 *tert*-Butyl 6-{{(trifluoromethyl)sulfonyl}oxy}-3,4-dihydro-2,7-naphthyridine-2(1*H*)-carboxylate (0.34 g, 0.90 mmol), 2-cyclopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (0.20 g, 0.82 mmol), PdCl₂ x dppf (0.050 g), saturated sodium carbonate (2 mL), EtOH (4 mL) and toluene (4 mL) were stirred at 80 °C for 2 h. The solution was cooled to RT, taken up in water (15 mL) and extracted three times with EtOAc-Et₂O. The combined organic phases were dried, filtered and concentrated. Purification by column chromatography with EtOAc-heptanes (1:1 through 3:1) and EtOAc-MeOH (9:1) as eluents gave 0.22 g (70%) of *tert*-butyl 6-(6-cyclopropylpyridin-3-yl)-3,4-dihydro-2,7-naphthyridine-2(1*H*)-carboxylate as a white solid.

10 LC-MS *m/z* 352 (M+1).

This material was dissolved in EtOAc (5 mL) and stirred with 1.5M hydrogen chloride in EtOAc (5 mL) at 50 °C for 4 h. The solvent was evaporated to leave the crude title compound (0.63 mmoles) in quantitative yield.

15 2-Cyclopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

0.5M Zinc chloride in THF (5.5 mL, 2.8 mmol) was added to a solution of 0.5M cyclopropylmagnesium bromide in THF (5.5 mL, 2.8 mmol) under argon. The solution was stirred at RT for 2 h at which time a slurry had formed. To this slurry was added in one portion 2,5-dibromopyridine (0.65 g, 2.8 mmol) and PdCl₂ x dppf (0.041 g, 0.050 mmol). After a few minutes an exotherm was seen and the slurry became thicker, the exotherm subsided and the slurry was stirred at RT overnight. The reaction mixture was poured into saturated sodium bicarbonate solution and extracted with ether. The ether phase was dried, filtered and concentrated, then re-dissolved in DCM and applied to a short plug of silica gel. The gel was washed with DCM and the washings were concentrated. The residue was taken up in ether and washed with 1.0M hydrochloric acid. The acidic water phase was made basic with 2.0M sodium hydroxide and the product was extracted back into ether. The combined ether phases were washed with brine, dried, filtered and concentrated to give 0.28 g (50%) of 5-bromo-2-cyclopropylpyridine as a yellow oil.

LC-MS *m/z* 197.9/199.9 (M+1);

30 ¹H-NMR(CDCl₃) δ 8.48 (d, 1H), 7.63 (dd, 1H), 7.04 (d, 1H), 1.99 (m, 1H), 1.03-0.98 (m, 4H) ppm.

5-Bromo-2-cyclopropylpyridine (0.21 g, 1.1 mmol), bis(pinacolato)diboron (0.31 g, 1.2 mmol) and potassium acetate (0.32 g, 3.2 mmol) were suspended in dioxane (10 mL). The slurry was degassed with argon for 10 minutes and then $PdCl_2 \times dppf$ (0.026 g) was added. The reaction mixture was heated to 80 °C for 15 h and then, after cooling to RT, filtered through a Celite plug. The filtrate was concentrated to give a black oil that was dissolved in ether and extracted four times with 1.0M sodium hydroxide. The combined yellow water phases were cooled to 10 °C, acidified with 2.5M hydrochloric acid to pH 6.5 and then extracted repeatedly with ether. The combined organic phases were dried over anhydrous magnesium sulfate, filtered and concentrated to give 0.27 g (103%) of the title product as a yellow oil that slowly solidified. 1H -NMR suggested a purity of about 60-65% of the required product, the major contaminant being pinacolborane. The crude material was used without further purification.

GC-MS m/z 245.2 (M+), 244.2 (M-1);

1H -NMR($CDCl_3$) δ 8.78 (br s, 1H), 7.93 (dd, 1H), 7.10 (d, 1H), 2.10 (m, 1H), 1.34 (s, 12H), 1.10-1.00 (m, 4H) ppm.

tert-Butyl 6-{{[trifluoromethyl]sulfonyl]oxy}-3,4-dihydro-2,7-naphthyridine-2(1H)-carboxylate

Crude 3-methoxy-2,7-naphthyridine (prepared from 4.4 mmoles of 6-methoxy-4-[(trimethylsilyl)ethynyl]nicotinaldehyde) was hydrogenated (30 psi pressure) at RT over PtO_2 (approx. 0.1 g) in HOAc (25 mL) for 2.5 h. The solution was filtered through a Celite pad and the clear filtrate was concentrated by freeze-drying to give crude 6-methoxy-1,2,3,4-tetrahydro-2,7-naphthyridine as the acetate.

LC-MS m/z 165 (M+1).

This material was refluxed in 48% hydrobromic acid for 10 h. The volatiles were evaporated and the residue was dried under vacuum at 45 °C to give crude 5,6,7,8-tetrahydro-2,7-naphthyridin-3-ol hydrobromide (approximately 0.70 g).

LC-MS m/z 151 (M+1).

This material (about 4.8 mmol) was dissolved in water (13 mL) and treated with THF (33 mL), Et_3N (0.85 mL, 6.0 mmol) and BOC-anhydride (1.6 g, 7.3 mmol) at RT. After stirring at the same temperature for 6 h the solution was concentrated to one third of its original volume and the residue was taken up in water and extracted three times with

EtOAc. The combined organic phases were dried, filtered and concentrated to give 0.80 g (67% crude yield) of *tert*-butyl 6-hydroxy-3,4-dihydro-2,7-naphthyridine-2(1*H*)-carboxylate as a white solid.

LC-MS *m/z* 251 (M+1), 195 (M-55).

5 This material (about 5.4 mmoles) was dissolved in a two-phase system of toluene (20 mL) and 30% aqueous tripotassium orthophosphate (20 mL), and treated with triflic anhydride (1.6 mL, 6.8 mmol) at 4 °C [Org. Lett. 2002, 4(26), 4717-4718]. The ice-bath was removed, the stirring continued for 2 h at RT after which the two phases were separated. The aqueous phase was washed once with toluene. The combined organic phases were 10 washed with brine, dried and concentrated. Purification by column chromatography with EtOAc-heptanes (2:1) as eluent gave 0.45 g (17% yield) of the title product.

LC-MS *m/z* 383 (M+1), 283 (M-99).

3-Methoxy-2,7-naphthyridine

15 To a stirred solution of *N,N,N'*-trimethylethylenediamine (1.9 mL, 15 mmol) in anhydrous THF (65 mL) under argon at -70 °C was slowly added 1.6M *n*-BuLi in hexanes (9.0 mL, 14 mmol). After stirring at -70 °C for 15 minutes, 6-methoxy-nicotinaldehyde (1.3 g, 9.8 mmol) was added dropwise. After the addition was complete, stirring was continued at -70 °C for another 15 minutes. Then 1.6M *n*-BuLi in hexanes (10 mL, 16 mmol) was 20 added dropwise and stirring continued at -45 °C for 4 h. The solution was cooled to -70 °C and then a solution of iodine (3.0 g, 12 mmol) in anhydrous THF (25 mL) was added dropwise. When the addition was complete, stirring was continued at -70 °C for 30 minutes and then at RT for 3 h. The crude product was taken up in ether (40 mL) and washed successively with saturated ammonium chloride (2 x 40 mL) and 5% sodium 25 thiosulfate (2 x 20 mL). The organic phase was dried, filtered and concentrated. Purification by column chromatography with EtOAc-heptanes (1:1) as eluent gave 0.41 g (15% yield) of 4-iodo-6-methoxynicotinaldehyde.

LC-MS *m/z* 264 (M+1);

¹H NMR (CDCl₃) δ 9.95 (s, 1H), 8.53 (s, 1H), 7.32 (s, 1H) and 3.98 (s, 3H) ppm.

and THF (10 mL) were stirred at 60 °C for 2 h. The volatiles were evaporated and the residue was taken up in water and extracted with ether. The organic phase was dried, filtered and concentrated. Purification by column chromatography with EtOAc-heptanes (1:3) as eluent gave 0.25 g (68% yield) of 6-methoxy-4-[(trimethylsilyl)ethynyl]nicotinaldehyde.

LC-MS *m/z* 234 (M+1);

¹H NMR (CDCl₃) δ 10.4 (s, 1H), 8.73 (s, 1H), 6.84 (s, 1H), 4.03 (s, 3H) and 0.30 (s, 9H) ppm.


10 6-Methoxy-4-[(trimethylsilyl)ethynyl]-nicotinaldehyde (0.25 g, 1.1 mmol) and 7M ammonia in MeOH (5 mL) were stirred in a sealed vial at 80 °C overnight. The solution was concentrated, taken up in saturated sodium carbonate and extracted with ether. The organic phase was dried, filtered and concentrated to give 0.20 g of the title product.

GC-MS *m/z* 160 (M⁺);

15 ¹H NMR (CDCl₃) δ 9.41 (s, 1H), 9.27 (s, 1H), 8.47 (d, 1H), 7.64 (d, 1H), 7.03 (s, 1H) and 4.12 (s, 3H) ppm.

Example 3 (5*S*)-5-({[6-(2-Cyclopropylpyrimidin-5-yl)-3,4-dihydro-2,7-naphthyridin-2(1*H*)-yl]sulfonyl}methyl)-5-methylimidazolidine-2,4-dione

20



To a stirred solution of 6-(2-cyclopropylpyrimidin-5-yl)-1,2,3,4-tetrahydro-2,7-naphthyridine hydrochloride (0.12 g, 0.42 mmol) in DCM (10 mL) was added TEA (0.12 mL, 0.84 mmol) followed by the dropwise addition of [(4*S*)-4-methyl-2,5-dioxoimidazolidin-4-yl]methanesulfonyl chloride (0.090 g, 0.40 mmol) in THF (10 mL) at -10 °C. The mixture was stirred at RT overnight, concentrated, taken up in water (10 mL) and extracted four times with EtOAc. The combined organic phases were dried, filtered


and concentrated. Purification by prep-HPLC gave 0.12 g (64%) of the title compound as a white solid.

LC-MS m/z 442.9 (M+1);

¹H NMR (CD₃OD) δ 9.05 (s, 2H), 8.43 (s, 1H), 7.81 (s, 1H), 4.63 (s, 2H), 3.40 (t, 2H),

5 3.38(q, 2H), 3.00 (t, 2H), 2.20 (m, 1H), 1.40 (s, 3H) and 1.05 (m, 4H) ppm.

Example 4 (5S)-5-((6-(2-Cyclopropylpyrimidin-5-yl)-3,4-dihydro-2,7-naphthyridin-2(1H)-yl)sulfonyl)methyl)-5-ethylimidazolidine-2,4-dione



10

The title compound was prepared by the general method of Example 3 but using [(4S)-4-ethyl-2,5-dioxoimidazolidin-4-yl)methane-sulfonyl chloride.

LC-MS m/z 457 (M+1).

15

The starting materials were prepared as follows:

6-(2-Cyclopropylpyrimidin-5-yl)-1,2,3,4-tetrahydro-2,7-naphthyridine hydrochloride

A mixture of 2-*tert*-butyl-6-(2-cyclopropylpyrimidin-5-yl)-1,2,3,4-tetrahydro-2,7-

20 naphthyridine (0.12 g, 0.39 mmol), 1-chloroethyl chloroformate (1.0 mL, 5.8 mmol) and toluene (10 mL) was refluxed for 4 h under protection from moisture (calcium chloride tube). After concentration to dryness, the dark residue was taken up in MeOH (10 mL) and refluxed for 3 h more. Charcoal (1 g) was added and refluxing continued for 20 minutes. Then the mixture was filtered through Celite and the clear filtrate was concentrated to give 25 the title compound (0.12 g) as a solid.

LC-MS m/z 253 (M+1);

¹H NMR(CDCl₃) δ 9.22 (s, 2H), 8.57 (s, 1H), 7.98 (s, 1H), 4.41 (s, 2H), 3.45 (t, 2H), 2.44 (m, 2H), 2.32 (m, 1H) and 1.21 (m, 4H) ppm.

2-*tert*-Butyl-6-(2-cyclopropylpyrimidin-5-yl)-1,2,3,4-tetrahydro-2,7-naphthyridine

To a stirred and cold (4 °C) solution of 2-*tert*-butyl-6-hydroxy-1,2,3,4-tetrahydro-2,7-naphthyridine (0.15 g, 0.73 mmol) in pyridine (5.0 mL) was slowly added triflic anhydride (0.14 mL, 0.80 mmol). When the addition was complete, the mixture was stirred at 4 °C for 30 minutes, quenched with 5% potassium carbonate solution (10 mL) and extracted four times with DCM. The combined organic phases were dried, filtered and concentrated to give a crude product. Column chromatography with EtOH-TBME (1:9) as eluent gave 0.30 g of the crude triflate as an oil.

10 LC-MS *m/z* 339.2 (M+1).

The triflate was dissolved in dioxane (10 mL) and anhydrous potassium acetate (0.43 g, 4.5 mmol), 2-cyclopropylpyrimidine-4-boronic acid (0.14 g, 0.89 mmol) and PdCl₂ x dppf (0.0050 g) were added. The mixture was degassed with argon, sealed and stirred at 90 °C overnight. After cooling, the solution was taken up in water (20 mL) and extracted three times with EtOAc. The combined organic phases were washed with brine, dried, filtered and concentrated. Column chromatography EtOH-TBME (1:9) and TBME-EtOH-TEA (20:2:1) gave 0.12 g (53% from two steps) of the title compound as a light brown solid.

LC-MS *m/z* 309 (M+1);

11 ¹H NMR (CDCl₃) 9.05 (s, 2H), 8.45 (s, 1H), 7.38 (s, 1H), 3.97 (m, 2H), 2.95 (m, 4H), 2.00 (m, 1H), 1.21 (s, 9H), 1.11(dt, 2H) and 1.09 (dt, 2H) ppm.

2-*tert*-Butyl-6-hydroxy-1,2,3,4-tetrahydro-2,7-naphthyridine

A solution of 2-*tert*-butyl-6-methoxy-1,2,3,4-tetrahydro-2,7-naphthyridine (5.1 g, 23 mmol) and 45% hydrobromic acid in acetic acid (70 mL) was heated in a sealed tube at 100 °C for 1 h, cooled to RT and concentrated. The residue was dissolved carefully in 20% potassium carbonate solution (100 mL) and extracted four times with EtOAc. The combined organic phases were dried, filtered and concentrated. Recrystallisation from TBME-hexanes gave 3.7 g (77%) of the title compound as a white solid.

LC-MS *m/z* 207 (M+1);

12 ¹H NMR (CDCl₃) δ 7.21 (s, 1H), 6.35 (s, 1H), 4.77 (m, 2H), 4.11 (m's, 4H) and 1.31 (s, 9H) ppm.

2-Cyclopropylpyrimidine-4-boronic acid

The title compound was prepared from 4-bromo-2-cyclopropylpyrimidine (WO 00/066566) in 90% yield (25 mmol scale) following the procedure by Li *et al.* (*J. Org. Chem.* 2002, 67, 5394-5397). LC-MS suggested that the product was composed of the boronic acid and the trimeric anhydride (*sym*-boroxine).

LC-MS m/z 165 (M+1) and 439 (M+1).

2-*tert*-Butyl-6-methoxy-1,2,3,4-tetrahydro-2,7-naphthyridine

To a stirred solution of 2,2,6,6-tetramethylpiperidine (9.0 mL, 60 mmol) in dry THF (300 mL) under argon at -20 °C was slowly added 1.6M *n*-BuLi in hexanes (40 mL, 60 mmol) while the temperature was kept at -20 °C. After the addition was complete, stirring was continued at -20 °C for 40 min. Then a solution of *tert*-butyl-[(6-methoxy-4-methylpyridin-3-yl)methylene]amine (6.3 g, 30 mmol) in dry THF (100 mL) was added dropwise at -20 °C. The mixture was stirred at -15 to -10 °C for 1.5 h and then cooled to -20 °C. Anhydrous DMF (6.5 ml, 70 mmol) was added dropwise over five minutes and stirring continued at -10 °C for 1.5 h. Then glacial acetic acid (60 mL) in MeOH (250 ml) was added, followed by the portion-wise addition of sodium cyanoborohydride (2.3 g, 40 mmol) over five minutes. After stirring overnight, the solvent was evaporated and 20% potassium carbonate solution was added slowly to raise the pH to 9. The mixture was extracted four times with TBME. The combined organic phases were washed with brine, dried and concentrated to give a crude oil. Vacuum distillation gave 5.2 g (77%) of the title compound as a colourless oil, b.p. 105-106 °C/0.5 mmHg.

GC-MS m/z 220.1 (M⁺);

¹H NMR (CDCl₃) δ 7.90 (s, 1H), 6.55 (s, 1H), 3.95 (s, 3H), 3.81 (m, 3H), 2.95-2.90 (m, 3H) and 1.11 (s, 9H) ppm.

tert-Butyl-[(6-methoxy-4-methylpyridin-3-yl)methylene]amine

2-Methoxy-4-methylnicotinaldehyde (1.8 g, 12 mmol), *tert*-butylamine (15 mL), 3Å molecular sieves (8 g) and dry DCM (10 mL) were mixed and allowed to stand at RT under protection from moisture (calcium chloride tube). After two days the mixture was filtered and the molecular sieves were washed several times with dry DCM. The combined

washings were concentrated to give 2.2 g (89%) of the title compound as a crude oil that was used immediately in the next step.

¹H NMR (CDCl₃) δ 8.55 (br s, 1H), 8.50 (s, 1H), 6.50 (s, 1H), 3.96 (s, 3H), 2.50 (s, 3H) and 1.30 (s, 9H) ppm.

5

2-Methoxy-4-methylnicotinaldehyde

To a stirred solution of 5-bromo-2-methoxy-4-methylpyridine (2.6 g, 13 mmol) in dry THF (40 mL) under argon at -70 °C was added 1.6M *n*-BuLi in hexanes (8.1 mL, 14 mmol) over ten minutes. The mixture was stirred at -70 °C for 30 minutes and then 10 anhydrous DMF (1.2 mL, 15 mmol) was added portion-wise at a rate that kept the temperature at -70 °C. When the addition was complete, the mixture was stirred at -70 °C for 30 minutes and then at RT overnight. The reaction was quenched with 1M hydrochloric acid (40 mL) and then extracted three times with TBME. The combined organic phases were washed with brine, dried, filtered and concentrated. Column chromatography with 15 TBME- light petroleum ether (1:1) as eluent gave 1.8 g (91%) of the title compound as pale yellow solid.


LC-MS *m/z* 152 (M+1);

¹H NMR (CDCl₃) δ 10.1 (s, 1H), 8.55 (s, 1H), 6.61 (s, 1H), 4.05 (s, 3H), 2.60 (s, 3H) ppm.

20 [(4*S*)-4-Ethyl-2,5-dioxoimidazolidin-4-yl]methanesulfonyl chloride

Prepared as described in WO 02/074767 for [(4*S*)-4-methyl-2,5-dioxoimidazolidin-4-yl]methanesulfonyl chloride.

25 Example 5 (5*S*)-5-({[6-(2-Cyclopropylpyrimidin-5-yl)-3,4-dihydroisoquinolin-2(1*H*)-yl]sulfonyl}methyl)-5-ethylimidazolidine-2,4-dione



The title compound was prepared by chiral chromatographic resolution of (\pm)-5-([6-(2-cyclopropylpyrimidin-5-yl)-3,4-dihydroisoquinolin-2(1*H*)-yl]sulfonyl)methyl)-5-ethylimidazolidine-2,4-dione using the procedure described in WO 02/074767.

5 Preparative chromatographic data:

Chiracel OD-H column (L 25 cm, \varnothing 2 cm) Daicel Chemical Industries Ltd.

Eluent: 100% EtOH Flow: 15 mL/ min Detection UV 254 nm.

Analytical chromatographic data

10 Chiralcel OD-H column (L 15 cm, \varnothing 0.46 cm) Daicel Chemical Industries Ltd.

Eluent: 100% EtOH Flow: 0.30 mL/ min Detection UV 254/220 nm.

Retention time (t_R) – see below

(S)-enantiomer (t_R 13.0 minutes)

15 1 H NMR (DMSO- d_6) δ 10.79 (br s, 1H), 8.94 (s, 2H), 7.97 (br s, 1H), 7.60 - 7.56 (m, 2H), 7.33 - 7.28 (m, 1H), 4.41 (s, 2H), 3.59 - 3.40 (m, 4H), 2.96 (t, J = 6.2 Hz, 2H), 2.28 - 2.21 (m, 1H), 1.65 (q, J = 7.6 Hz, 2H), 1.11 - 1.00 (m, 4H) and 0.78 (t, J = 7.5 Hz, 3H) ppm.

(R)-enantiomer (t_R 18.3 minutes)

20 1 H NMR (DMSO- d_6) δ 10.79 (br s, 1H), 8.94 (s, 2H), 7.97 (br s, 1H), 7.60 - 7.56 (m, 2H), 7.32 - 7.28 (m, 1H), 4.41 (s, 2H), 3.58 - 3.40 (m, 4H), 2.96 (t, J = 6.2 Hz, 2H), 2.28 - 2.21 (m, 1H), 1.65 (q, J = 7.6 Hz, 2H), 1.11 - 1.00 (m, 4H) and 0.78 (t, J = 7.5 Hz, 3H) ppm.

(\pm)-5-([6-(2-Cyclopropylpyrimidin-5-yl)-3,4-dihydroisoquinolin-2(1*H*)-

25 yl]sulfonyl)methyl)-5-ethylimidazolidine-2,4-dione)

The title compound was prepared from 6-(2-cyclopropylpyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline according to the procedure described in WO 02/074767.


LC-MS m/z 456 (M+1);

1 1 H NMR (DMSO- d_6) δ 10.78 (br s, 1H), 8.94 (s, 2H), 8.03 (br s, 1H), 7.61 - 7.56 (m, 2H),

30 7.30 (d, J = 8.5 Hz, 1H), 4.42 (s, 2H), 3.60 - 3.40 (m, 4H), 2.96 (t, J = 6.2 Hz, 2H), 2.26 -

2.20 (m, 1H), 1.65 (q, $J = 7.2$ Hz, 2H), 1.10 - 1.01 (m, 4H) and 0.78 (t, $J = 7.5$ Hz, 3H) ppm.

Example 6 (5S)-5-({[6-(2-Cyclobutylpyrimidin-5-yl)-3,4-dihydroisoquinolin-2(1H)-yl]sulfonyl}methyl)-5-methylimidazolidine-2,4-dione



The title compound was prepared using the method described for Example 1.

LC-MS m/z 456 (M+1);

11 H NMR (300 MHz, DMSO-d6) δ 1.31 (s, 3H), 1.83 - 2.12 (m, 2H), 2.26 - 2.45 (m, 4H), 2.96 (s, 2H), 3.19 - 3.55 (m, 4H), 3.78 (q, 1H), 4.43 (s, 2H), 6.92 (s, 1H), 7.32 (d, 1H), 7.60 (s, 2H), 9.04 (s, 2H), 10.81 (s, 1H) ppm.

The required starting materials were also prepared using the general methods described in

Example 1:

1,1-Dimethylethyl 6-(2-cyclobutylpyrimidin-5-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate

LC-MS m/z 366 (M+1);

11 H NMR (300 MHz, CDCl₃) δ 8.81 (s, 2H), 7.13 - 7.37 (m, 3H), 4.55 (d, 2H), 3.64 (t, 2H), 2.82 - 2.90 (m, 2H), 2.30 - 2.50 (m, 6H), 1.84 - 2.14 (m, 1H), 1.45 (s, 9H) ppm.

6-(2-Cyclobutylpyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinolinium chloride

LC-MS m/z 266 (M+1);


¹H NMR (300 MHz, DMSO-d6) δ 1.69 - 1.84 (m, 1H), 1.86 - 2.05 (m, 2H), 2.08 - 2.32 (m, 3H), 3.29 - 3.42 (m, 1H), 8.85 (s, 4H) ppm.

5-Bromo-2-cyclobutylpyrimidine

5 GC-MS *m/z* 211/213 (M);

¹H NMR (300 MHz, CDCl₃) δ 1.88 - 2.17 (m, 2H), 2.36 - 2.46 (m, 4H), 3.78 (td, 1H), 8.72 (s, 2H) ppm.

10 **Example 7** (5S)-5-Methyl-5-((6-[2-(1-methylcyclopropyl)pyrimidin-5-yl]-3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)methyl)imidazolidine-2,4-dione



The title compound was prepared using the method described for Example 1.

15 LC-MS *m/z* 456 (M+1);

¹H NMR (300 MHz, DMSO-d6) δ 0.94 (q, 2H), 1.30 (d, 2H), 1.34 (s, 3H), 1.54 (s, 3H), 2.96 (t, 2H), 3.40 - 3.62 (m, 4H), 4.42 (s, 2H), 7.31 (d, 1H), 7.58 (d, 2H), 8.06 (s, 1H), 8.97 (s, 2H), 10.77 (s, 1H) ppm.

20 The required starting materials were also prepared using the general methods described in Example 1:

6-[2-(1-Methylcyclopropyl)pyrimidin-5-yl]-1,2,3,4-tetrahydroisoquinolinium chloride

LC-MS m/z 266 (M+1);

¹H NMR (300 MHz, DMSO-d₆) δ 0.94 (q, 2H), 1.30 (q, 2H), 1.53 (s, 3H), 2.96 - 3.14 (m, 2H), 3.29 - 3.42 (m, 2H), 4.18 - 4.32 (m, 2H), 5.81 (s, 1H), 7.15 - 7.27 (m, 1H), 7.36 (t, 1H), 7.63 (d, 1H), 8.98 (s, 2H), 9.85 (s, 1H) ppm.

5 Imino(1-methylcyclopropyl)methanaminium chloride


¹H NMR (300 MHz, DMSO-d₆) δ 0.46 (dd, 2H), 0.91 (q, 2H), 1.21 (s, 3H), 7.35 (s, 4H) ppm.

5-Bromo-2-(1-methylcyclopropyl)pyrimidine

10 LC-MS *m/z* 213/215 (M+1);

¹H NMR (399.988 MHz, CDCl₃) δ 0.93 (dd, 2H), 1.35 (dd, 2H), 1.54 (s, 3H), 8.59 (s, 2H) ppm.

15 **Example 8 (5S)-5-Cyclopropyl-5-({[6-(2-cyclopropylpyrimidin-5-yl)-3,4-dihydroisoquinolin-2(1H)-yl]sulfonyl}methyl)imidazolidine-2,4-dione**



The title compound was prepared from 6-[2-(cyclopropyl)pyrimidin-5-yl]-1,2,3,4-tetrahydroisoquinoline and (4S)-(4-cyclopropyl-2,5-dioxoimidazolidin-4-yl)methanesulfonyl chloride using the general method described in Example 1.

LC-MS *m/z* 468 (M+1);

¹H NMR (400 MHz, DMSO-d₆) δ 0.18 (q, 1H), 0.33 - 0.56 (m, 3H), 1.02 - 1.17 (m, 5H), 2.24 (dd, 1H), 2.96 (t, 2H), 3.40 - 3.82 (m, 4H), 4.43 (s, 2H), 7.31 (t, 1H), 7.58 (d, 2H), 7.95 (s, 1H), 8.94 (s, 2H), 10.74 (s, 1H) ppm.

The required starting materials were prepared as follows:

2-Benzylsulfanyl-1-cyclopropyl-ethanone

Benzyl mercaptan (15.6 ml, 0.133 mol) was stirred in DCM (100 ml), triethylamine (20.5 ml, 0.146 mol) added, the mixture cooled in an ice / acetone bath and 2-bromo-1-cyclopropyl-ethanone, prepared as in WO 03/074495, (21.77 g, 0.133 mol) dissolved in DCM (100 ml) was added dropwise. The mixture was stirred for 48 h, washed with water, then brine, dried over sodium sulphate and evaporated.

GC-MS *m/z* 206 (M);

¹H NMR (400 MHz, CDCl₃) δ 0.86 - 0.91 (m, 2H), 0.99 - 1.03 (m, 2H), 2.05 - 2.16 (m, 1H), 3.22 (s, 2H), 3.64 (s, 2H), 7.18 - 7.31 (m, 5H) ppm.

This material was used without any further purification.

15 Benzylsulfanylmethyl-5-cyclopropyl-imidazolidine-2,4-dione

2-Benzylsulfanyl-1-cyclopropyl-ethanone (27.55 g, 0.133 mol) was dissolved in ethanol (250 ml) and dispensed into 20 x 40 ml vials. Sodium cyanide (6.52 g, 0.133 mol) and ammonium carbonate (64 g, 0.667 mol) were dissolved in water (250 ml) and divided into the vials, which were then sealed and heated at 90 °C for 5 h behind a safety screen. After cooling to room temperature, the contents of the vials were combined, TBME was added, and the mixture was washed with water (x 2), brine (x 1), and then dried over sodium sulphate. Evaporation then gave the crude product (16.5 g, 45%). This material was absorbed onto silica and chromatographed (5 x 9.5cm column of silica) eluting with iso-hexane to 50% ethyl acetate : iso-hexane to yield the title compound (11.81 g, 32.1%).

25 LC-MS *m/z* 277 (M+1);

¹H NMR (400 MHz, CDCl₃) δ 0.23 - 0.59 (m, 4H), 1.12 - 1.19 (m, 1H), 2.87 (dd, 2H), 3.67 - 3.74 (m, 2H), 6.06 (s, 1H), 7.15 - 7.33 (m, 5H), 8.66 (s, 1H) ppm.

30 The isomers were separated on a Chiraldak AD semi-prep column.

Eluent: 65% Ethanol / 35% iso-hexane

Concentration: 50 mg per ml

Injection volume: 2 ml


5 Run time: 21 mins

Chiral analysis on a Chiraldak AD 25 x 0.46 cm column, 0.7 ml / min gave retention times of 8.9 and 11.5 min. The faster running isomer was used for further reactions.

10 ^1H NMR (400 MHz, CDCl_3) δ 0.19 - 0.58 (m, 4H), 1.10 - 1.24 (m, 1H), 2.86 (dd, 2H), 3.62 - 3.78 (m, 2H), 5.87 (s, 1H), 7.16 - 7.34 (m, 5H), 8.51 (s, 1H) ppm.

(4S)-(4-Cyclopropyl-2,5-dioxoimidazolidin-4-yl)methanesulfonyl chloride

15



20

(5S)-Benzylsulfonylmethyl-5-cyclopropyl-imidazolidine-2,4-dione (770 mg, 2.78 mmol) was dissolved in 90% acetic acid (100 ml) and cooled in an ice water bath whilst chlorine gas was bubbled through for 10 minutes. The reaction mixture was freeze dried to give the title compound as a white solid (640 mg, 91%).

^1H NMR (400 MHz, THF) δ 0.37 - 0.65 (m, 4H), 1.25 - 1.33 (m, 1H), 4.62 (dd, 2H), 7.39 (s, 1H), 9.86 (s, 1H) ppm.

Pharmacological Example

Isolated Enzyme Assays

5

MMP12

Recombinant human MMP12 catalytic domain may be expressed and purified as described by Parkar A.A. *et al*, (2000), Protein Expression and Purification, 20, 152. The purified enzyme can be used to monitor inhibitors of activity as follows: MMP12 (50 ng/ml final concentration) is incubated for 60 minutes at room temperature with the synthetic substrate Mca-Pro-Cha-Gly-Nva-His-Ala-Dpa-NH₂ (10 μ M) in assay buffer (0.1M “Tris-HCl” (trade mark) buffer, pH 7.3 containing 0.1M NaCl, 20mM CaCl₂, 0.020 mM ZnCl and 0.05% (w/v) “Brij 35” (trade mark) detergent) in the presence (10 concentrations) or absence of inhibitors. Activity is determined by measuring the fluorescence at λ_{ex} 320 nm and λ_{em} 405 nm. Percent inhibition is calculated as follows:

% Inhibition is equal to the [Fluorescence_{plus inhibitor} - Fluorescence_{background}] divided by the [Fluorescence_{minus inhibitor} - Fluorescence_{background}].

MMP8

Purified pro-MMP8 is purchased from Calbiochem. The enzyme (at 10 μ g/ml) is activated by p-amino-phenyl-mercuric acetate (APMA) at 1 mM for 2.5 h, 35 °C. The activated enzyme can be used to monitor inhibitors of activity as follows: MMP8 (200 ng/ml final concentration) is incubated for 90 minutes at 35 °C (80% H₂O) with the synthetic substrate Mca-Pro-Cha-Gly-Nva-His-Ala-Dpa-NH₂ (12.5 μ M) in assay buffer (0.1M “Tris-HCl” (trade mark) buffer, pH 7.5 containing 0.1M NaCl, 30mM CaCl₂, 0.040 mM ZnCl and 0.05% (w/v) “Brij 35” (trade mark) detergent) in the presence (10 concentrations) or absence of inhibitors. Activity is determined by measuring the fluorescence at λ_{ex} 320 nm and λ_{em} 405 nm. Percent inhibition is calculated as follows:

% Inhibition is equal to the [Fluorescence_{plus inhibitor} - Fluorescence_{background}] divided by the [Fluorescence_{minus inhibitor} - Fluorescence_{background}].

MMP9

Recombinant human MMP9 catalytic domain was expressed and then purified by Zn chelate column chromatography followed by hydroxamate affinity column

5 chromatography. The enzyme can be used to monitor inhibitors of activity as follows:

MMP9 (5 ng/ml final concentration) is incubated for 30 minutes at RT with the synthetic substrate Mca-Pro-Cha-Gly-Nva-His-Ala-Dpa-NH₂ (5 μ M) in assay buffer (0.1M "Tris-HCl" (trade mark) buffer, pH 7.3 containing 0.1M NaCl, 20mM CaCl₂, 0.020 mM ZnCl and 0.05% (w/v) "Brij 35" (trade mark) detergent) in the presence (10 concentrations) or

10 absence of inhibitors. Activity is determined by measuring the fluorescence at λ_{ex} 320 nm and λ_{em} 405 nm. Percent inhibition is calculated as follows:

% Inhibition is equal to the [Fluorescence_{plus inhibitor} - Fluorescence_{background}] divided by the [Fluorescence_{minus inhibitor} - Fluorescence_{background}].

15 **MMP14**

Recombinant human MMP14 catalytic domain may be expressed and purified as described by Parkar A.A. *et al.*, (2000), Protein Expression and Purification, 20, 152. The purified enzyme can be used to monitor inhibitors of activity as follows: MMP14 (10 ng/ml final concentration) is incubated for 60 minutes at room temperature with the synthetic substrate

20 Mca-Pro-Cha-Gly-Nva-His-Ala-Dpa-NH₂ (10 μ M) in assay buffer (0.1M "Tris-HCl" (trade mark) buffer, pH 7.5 containing 0.1M NaCl, 20mM CaCl₂, 0.020 mM ZnCl and 0.05% (w/v) "Brij 35" (trade mark) detergent) in the presence (5 concentrations) or absence of inhibitors. Activity is determined by measuring the fluorescence at λ_{ex} 320 nm and λ_{em} 405 nm. Percent inhibition is calculated as follows: % Inhibition is equal to the

25 [Fluorescence_{plus inhibitor} - Fluorescence_{background}] divided by the [Fluorescence_{minus inhibitor} - Fluorescence_{background}].

A protocol for testing against other matrix metalloproteinases, including MMP9, using expressed and purified pro MMP is described, for instance, by C. Graham Knight *et al.*,

30 (1992) FEBS Lett., 296(3), 263-266.

MMP19

Recombinant human MMP19 catalytic domain may be expressed and purified as described by Parkar A.A. *et al*, (2000), Protein Expression and Purification, 20:152. The purified enzyme can be used to monitor inhibitors of activity as follows: MMP19 (40 ng/ml final concentration) is incubated for 120 minutes at 35 °C with the synthetic substrate Mca-Pro-5 Leu-Ala-Nva-Dpa-Ala-Arg-NH₂ (5 μM) in assay buffer (0.1M “Tris-HCl” (trade mark) buffer, pH 7.3 containing 0.1M NaCl, 20mM CaCl₂, 0.020 mM ZnCl and 0.05% (w/v) “Brij 35” (trade mark) detergent) in the presence (5 concentrations) or absence of 10 inhibitors. Activity is determined by measuring the fluorescence at λ_{ex} 320 nm and λ_{em} 405 nm. Percent inhibition is calculated as follows: % Inhibition is equal to the [Fluorescence_{plus inhibitor} - Fluorescence_{background}] divided by the [Fluorescence_{minus inhibitor} - Fluorescence_{background}].

15

The following table shows data for a representative selection of the compounds of the present invention.

Table

20


Compound	hMMP12 IC ₅₀ (nM)	hMMP9 IC ₅₀ (nM)	hMMP8 IC ₅₀ (nM)	hMMP14 IC ₅₀ (nM)	hMMP19 IC ₅₀ (nM)
Example 1	8.78	10.1	3050	> 10000	> 10000
Example 2	26.6	21.5	2470	> 10000	> 10000
Example 5	6.9	3.8	1310	8810	3760

25

C L A I M S

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof

5



wherein

10 R¹ represents cyclobutyl or cyclopropyl; said cyclopropyl group being optionally further substituted by CH₃, CN or one or two fluoro atoms;

R² represents C1 to 3 alkyl or cyclopropyl; and

15 A, A¹ and B independently represent CH or N;

2. A compound according to Claim 1, wherein R¹ represents cyclopropyl.

3. A compound according to Claim 1 or Claim 2, wherein R² represents methyl or ethyl.

20

4. A compound according to any one of Claims 1 to 3, wherein B¹ represents CH.

5. A compound according to any one of Claims 1 to 4, wherein A and A¹ each represent N.

6. A compound according to Claim 1 which is selected from the group consisting of:

(5*S*)-5-({[6-(2-cyclopropylpyrimidin-5-yl)-3,4-dihydroisoquinolin-2(1*H*)-

yl]sulfonyl}methyl)-5-methylimidazolidine-2,4-dione;

5 (5*S*)-5-({[6-(6-cyclopropylpyridin-3-yl)-3,4-dihydro-2,7-naphthyridin-2(1*H*)-

yl]sulfonyl}methyl)-5-methylimidazolidine-2,4-dione;

(5*S*)-5-({[6-(2-cyclopropylpyrimidin-5-yl)-3,4-dihydro-2,7-naphthyridin-2(1*H*)-

yl]sulfonyl}methyl)-5-methylimidazolidine-2,4-dione;

(5*S*)-5-({[6-(2-cyclopropylpyrimidin-5-yl)-3,4-dihydro-2,7-naphthyridin-2(1*H*)-

10 yl]sulfonyl}methyl)-5-ethylimidazolidine-2,4-dione;

(5*S*)-5-({[6-(2-cyclopropylpyrimidin-5-yl)-3,4-dihydroisoquinolin-2(1*H*)-

yl]sulfonyl}methyl)-5-ethylimidazolidine-2,4-dione;

(5*S*)-5-({[6-(2-cyclobutylpyrimidin-5-yl)-3,4-dihydroisoquinolin-2(1*H*)-

yl]sulfonyl}methyl)-5-methylimidazolidine-2,4-dione;

15 (5*S*)-5-methyl-5-({[6-[2-(1-methylcyclopropyl)pyrimidin-5-yl]-3,4-dihydroisoquinolin-

2(1*H*)-yl]sulfonyl}methyl)imidazolidine-2,4-dione;

(5*S*)-5-Cyclopropyl-5-({[6-(2-cyclopropylpyrimidin-5-yl)-3,4-dihydroisoquinolin-2(1*H*)-


yl]sulfonyl}methyl)imidazolidine-2,4-dione;

and pharmaceutically acceptable salts thereof.

20

7. A process for the preparation of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof which comprises:


a) reaction of a compound of formula (II)



(II)

25

wherein R^2 is as defined in formula (I) and L^1 represents a leaving group, with a compound of formula (III) (or a salt thereof)




(III)

5


wherein R^1 , A , A^1 and B are as defined in formula (I); or

b) reaction of a compound of formula (V)



(V)


10 wherein R^2 and B are as defined in formula (I) and LG is a leaving group; with a boronic acid derivative of formula (XII)



(XII)

15 wherein R^1 , A and A^1 are as defined in formula (I); or

c) reaction of a compound of formula (IX)



5 wherein R¹, R², A, A¹ and B are as defined in formula (I); with ammonium carbonate and potassium cyanide;
and optionally thereafter forming a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition comprising a compound of formula (I) or a
10 pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 6 in
association with a pharmaceutically acceptable adjuvant, diluent or carrier.

9. A process for the preparation of a pharmaceutical composition as claimed in claim 8
which comprises mixing a compound of formula (I) or a pharmaceutically acceptable salt
15 thereof as defined in any one of claims 1 to 6 with a pharmaceutically acceptable adjuvant,
diluent or carrier.

10. A compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed
in any one of claims 1 to 6 for use in therapy.

20

11. Use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as
claimed in any one of claims 1 to 6 in the manufacture of a medicament for use in the
treatment of an obstructive airways disease.

12. Use according to claim 11, wherein the obstructive airways disease is asthma or chronic obstructive pulmonary disease.

13. Use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as
5 claimed in any one of claims 1 to 6 in the manufacture of a medicament for use in the treatment of rheumatoid arthritis, osteoarthritis, atherosclerosis, cancer or multiple sclerosis.

14. A method of treating a disease or condition mediated by MMP12 and/or MMP9
10 which comprises administering to a patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 6.

15. A method of treating an obstructive airways disease which comprises administering to a patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 6.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE2005/001917

A. CLASSIFICATION OF SUBJECT MATTER

IPC: see extra sheet

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC: C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, PAJ, CHEM ABS DATA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 02074767 A1 (ASTRAZENECA AB), 26 Sept 2002 (26.09.2002) --	1-15
A	WO 2004024718 A1 (ASTRAZENECA AB), 25 March 2004 (25.03.2004) --	1-15
A	WO 02074750 A1 (ASTRAZENECA AB), 26 Sept 2002 (26.09.2002) --	1-15
A	WO 2004033632 A2 (BRISTOL-MYERS SQUIBB COMPANY), 22 April 2004 (22.04.2004) --	1-15

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

8 March 2006

Date of mailing of the international search report

13-03-2006

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. + 46 8 666 02 86

Authorized officer

Eva Johansson/EÖ
Telephone No. + 46 8 782 25 00

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/SE2005/001917**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 14-15
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 14-15 relate to a method of treatment of the human or animal body by surgery or by therapy, as well as diagnostic
.../...
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No. PCT/SE2005/001917
--

Box II.1

methods /Rule 39.1(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE2005/001917

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2004024715 A1 (ASTRAZENECA AB), 25 March 2004 (25.03.2004) --	1-15
A	WO 2004108086 A2 (BRISTOL-MYERS SQUIBB COMPANY), 16 December 2004 (16.12.2004) -----	1-15

International patent classification (IPC)

C07D 401/14 (2006.01)
A61K 31/444 (2006.01)
A61K 31/506 (2006.01)
A61P 11/06 (2006.01)
A61P 19/02 (2006.01)
A61P 35/00 (2006.01)
A61P 9/10 (2006.01)
C07D 471/04 (2006.01)

Download your patent documents at www.prv.se

Cited patent documents can be downloaded at www.prv.se by following the links e-tjänster/anfördra dokument. Use the application number as username. The password is **7tmv9ktail**.

Paper copies can be ordered at a cost of 50 SEK per copy from PRV InterPat (telephone number 08-782 28 85).

Cited literature, if any, will be enclosed in paper form.

INTERNATIONAL SEARCH REPORT

Information on patent family members

31/12/2005

International application No.

PCT/SE2005/001917

WO	02074767	A1	26/09/2002	AU	5282101 A	26/11/2001
				BR	0207983 A	15/06/2004
				BR	0207984 A	15/06/2004
				BR	0208104 A	02/03/2004
				BR	0208105 A	09/03/2004
				CA	2440473 A	26/09/2002
				CA	2440630 A	26/09/2002
				CA	2440631 A	26/09/2002
				CA	2440632 A	26/09/2002
				CN	1509272 A	30/06/2004
				CN	1509275 A	30/06/2004
				CN	1509276 A	30/06/2004
				CN	1509286 A	30/06/2004
				CZ	20032497 A	18/02/2004
				CZ	20032499 A	17/03/2004
				CZ	20032500 A	18/02/2004
				CZ	20032502 A	14/01/2004
				EE	200300439 A	15/12/2003
				EE	200300445 A	15/12/2003
				EE	200300449 A	15/12/2003
				EE	200300451 A	15/12/2003
				EP	1370534 A	17/12/2003
				EP	1370536 A	17/12/2003
				EP	1370537 A	17/12/2003
				EP	1370556 A	17/12/2003
				HU	0400194 A	28/07/2004
				HU	0400202 A	30/08/2004
				HU	0400206 A	30/08/2004
				HU	0400327 A	28/01/2005
				IL	157570 D	00/00/0000
				IL	157652 D	00/00/0000
				IL	157656 D	00/00/0000
				IL	157657 D	00/00/0000
				JP	2004523581 T	05/08/2004
				JP	2004523583 T	05/08/2004
				JP	2004527511 T	09/09/2004
				JP	2004527515 T	09/09/2004
				MX	PA03008177 A	12/12/2003
				MX	PA03008180 A	12/12/2003
				MX	PA03008181 A	12/12/2003
				MX	PA03008191 A	29/01/2004
				NO	20034025 A	13/11/2003
				NO	20034042 A	10/11/2003
				NO	20034044 A	10/11/2003
				NO	20034045 A	10/11/2003
				NZ	528106 A	24/03/2005
				NZ	528107 A	24/06/2005
				NZ	528140 A	25/02/2005
				PL	364706 A	13/12/2004
				PL	364707 A	13/12/2004
				PL	364714 A	13/12/2004
				PL	365099 A	27/12/2004
				RU	2003127732 A	20/03/2005
				RU	2003127733 A	20/03/2005
				RU	2003127734 A	20/03/2005

INTERNATIONAL SEARCH REPORT

Information on patent family members

31/12/2005

International application No.

PCT/SE2005/001917

WO	02074767	A1	26/09/2002	RU	2003127735	A	20/03/2005
				SE	0100902	D	00/00/0000
				SK	10922003	A	04/05/2004
				SK	10932003	A	06/04/2004
				SK	10952003	A	04/05/2004
				SK	10962003	A	02/03/2004
				US	20040106659	A	03/06/2004
				US	20040127528	A	01/07/2004
				US	20040138276	A	15/07/2004
				US	20040147573	A	29/07/2004
				WO	02074748	A	26/09/2002
				WO	02074750	A	26/09/2002
				WO	02074751	A	26/09/2002
				ZA	200306731	A	29/11/2004
				ZA	200306732	A	29/11/2004
				ZA	200306734	A	29/11/2004
				ZA	200306737	A	29/11/2004
WO	2004024718	A1	25/03/2004	AU	2003258942	A	00/00/0000
				SE	0202693	D	00/00/0000

INTERNATIONAL SEARCH REPORT

Information on patent family members

31/12/2005

International application No.

PCT/SE2005/001917

WO	02074750	A1	26/09/2002	AU	5282101	A	26/11/2001
				BR	0207983	A	15/06/2004
				BR	0207984	A	15/06/2004
				BR	0208104	A	02/03/2004
				BR	0208105	A	09/03/2004
				CA	2440473	A	26/09/2002
				CA	2440630	A	26/09/2002
				CA	2440631	A	26/09/2002
				CA	2440632	A	26/09/2002
				CN	1509272	A	30/06/2004
				CN	1509275	A	30/06/2004
				CN	1509276	A	30/06/2004
				CN	1509286	A	30/06/2004
				CZ	20032497	A	18/02/2004
				CZ	20032499	A	17/03/2004
				CZ	20032500	A	18/02/2004
				CZ	20032502	A	14/01/2004
				EE	200300439	A	15/12/2003
				EE	200300445	A	15/12/2003
				EE	200300449	A	15/12/2003
				EE	200300451	A	15/12/2003
				EP	1370534	A	17/12/2003
				EP	1370536	A	17/12/2003
				EP	1370537	A	17/12/2003
				EP	1370556	A	17/12/2003
				HU	0400194	A	28/07/2004
				HU	0400202	A	30/08/2004
				HU	0400206	A	30/08/2004
				HU	0400327	A	28/01/2005
				IL	157570	D	00/00/0000
				IL	157652	D	00/00/0000
				IL	157656	D	00/00/0000
				IL	157657	D	00/00/0000
				JP	2004523581	T	05/08/2004
				JP	2004523583	T	05/08/2004
				JP	2004527511	T	09/09/2004
				JP	2004527515	T	09/09/2004
				MX	PA03008177	A	12/12/2003
				MX	PA03008180	A	12/12/2003
				MX	PA03008181	A	12/12/2003
				MX	PA03008191	A	29/01/2004
				NO	20034025	A	13/11/2003
				NO	20034042	A	10/11/2003
				NO	20034044	A	10/11/2003
				NO	20034045	A	10/11/2003
				NZ	528106	A	24/03/2005
				NZ	528107	A	24/06/2005
				NZ	528140	A	25/02/2005
				PL	364706	A	13/12/2004
				PL	364707	A	13/12/2004
				PL	364714	A	13/12/2004
				PL	365099	A	27/12/2004
				RU	2003127732	A	20/03/2005
				RU	2003127733	A	20/03/2005
				RU	2003127734	A	20/03/2005

INTERNATIONAL SEARCH REPORT

Information on patent family members

31/12/2005

International application No.

PCT/SE2005/001917

WO	02074750	A1	26/09/2002	RU	2003127735	A	20/03/2005
				SE	0100902	D	00/00/0000
				SK	10922003	A	04/05/2004
				SK	10932003	A	06/04/2004
				SK	10952003	A	04/05/2004
				SK	10962003	A	02/03/2004
				US	20040106659	A	03/06/2004
				US	20040127528	A	01/07/2004
				US	20040138276	A	15/07/2004
				US	20040147573	A	29/07/2004
				WO	02074748	A	26/09/2002
				WO	02074751	A	26/09/2002
				WO	02074767	A	26/09/2002
				ZA	200306731	A	29/11/2004
				ZA	200306732	A	29/11/2004
				ZA	200306734	A	29/11/2004
				ZA	200306737	A	29/11/2004
				AU	5282201	A	12/11/2001
				BR	0207985	A	15/06/2004
				BR	0208062	A	02/03/2004
				CA	2440475	A	26/09/2002
				CA	2444526	A	26/09/2002
				CN	1509273	A	30/06/2004
				CN	1509274	A	30/06/2004
				CZ	20032498	A	17/03/2004
				CZ	20032501	A	18/02/2004
				EE	200300450	A	15/12/2003
				EE	200300452	A	16/02/2004
				EP	1370535	A	17/12/2003
				EP	1370538	A	17/12/2003
				HU	0400193	A	28/07/2004
				HU	0400328	A	28/09/2004
				IL	157650	D	00/00/0000
				IL	157658	D	00/00/0000
				JP	2004523582	T	05/08/2004
				JP	2004527512	T	09/09/2004
				MX	PA03008183	A	12/12/2003
				MX	PA03008187	A	29/01/2004
				NO	20034027	A	05/11/2003
				NO	20034032	A	10/11/2003
				NZ	528108	A	29/04/2005
				NZ	528141	A	27/05/2005
				PL	364705	A	13/12/2004
				PL	365107	A	27/12/2004
				RU	2003127731	A	20/03/2005
				RU	2003127736	A	27/03/2005
				SE	0100903	D	00/00/0000
				SK	10912003	A	04/05/2004
				SK	10942003	A	06/04/2004
				US	20040110809	A	10/06/2004
				US	20040116486	A	17/06/2004
				WO	02074749	A	26/09/2002
				WO	02074752	A	26/09/2002
				ZA	200306733	A	29/11/2004
				ZA	200306738	A	29/11/2004

INTERNATIONAL SEARCH REPORT

Information on patent family members

31/12/2005

International application No.

PCT/SE2005/001917

WO	2004033632	A2	22/04/2004	AU	2003282920	A	04/05/2004
		EP		1546109	A	29/06/2005	
		US		20040067996	A	08/04/2004	
<hr/>				<hr/>			
WO	2004024715	A1	25/03/2004	AU	2003263345	A	00/00/0000
				AU	2003263347	A	00/00/0000
				BR	0314275	A	09/08/2005
				CA	2497571	A	25/03/2004
				CN	1681804	A	12/10/2005
				EP	1539740	A	15/06/2005
				EP	1551826	A	13/07/2005
				GB	0221246	D	00/00/0000
				NO	20051788	A	13/06/2005
				US	20050256176	A	17/11/2005
				WO	2004024721	A	25/03/2004
<hr/>				<hr/>			
WO	2004108086	A2	16/12/2004	US	20040254231	A	16/12/2004
				US	20050043269	A	24/02/2005
				US	20050043394	A	24/02/2005
				US	20050065110	A	24/03/2005